Do you want to read an article? Please log in or register.
Immunotherapy for Early-Stage Non-Small Cell Lung Cancer: A Practical Guide of Current Controversies
Lung Cancer
Related content
Lung Cancer
Management of Patients with Early-Stage Non-Small Cell Lung Cancer: An American College of Chest Physicians Clinical Practice Guideline
Chest
Howington J, Souter LH, Arenberg D, Blasberg J, Detterbeck F, Farjah F, Lanuti M, Leighl N, Videtic GM, Murthy S
doi: 10.1016/j.chest.2025.06.023
Lung Cancer
Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
J Clin Med
Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A, Karner J, Gruber G, Stana M, Minasch D, Kirchhammer K, Steffal C, Stranzl H, Moosbrugger R, Feurstein P, Dieckmann K, Zehentmayr F, ALLSTAR Group
doi: 10.3390/jcm14030945
Lung Cancer
Neoadjuvant therapy in early-stage non-small cell lung cancer: A real-world analysis
Lung Cancer
Ay L, Steiner D, Fabikan H, Illini O, Krenbek D, Klikovits T, Benej M, Kirchbacher K, Watzka S, Valipour A, Hochmair M
doi: 10.1016/j.lungcan.2024.107997
RECOMMENDED
Lung Cancer
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A
doi: 10.1016/j.lungcan.2024.108059
RECOMMENDED
Lung Cancer
An international and multidisciplinary EORTC survey on resectability of stage III non-small cell lung cancer
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Houda I, Bahce I, Dickhoff C, Kroese TE, Kroeze SGC, Mariolo AV, Tagliamento M, Moliner L, Brandão M, Pretzenbacher Y, Edwards J, Opitz I, Brunelli A, Guckenberger M, van Schil PE, Popat S, Blum T, Faivre-Finn C, de Ruysscher D, Remon J, Berghmans T, Dingemans AC, Besse B, Hendriks LEL
doi: 10.1016/j.lungcan.2024.108061
Lung Cancer
Segmentectomy vs. Lobectomy in stage IA non-small cell lung cancer: A systematic review and meta-analysis of perioperative and survival outcomes
Lung Cancer
Bertolaccini L, Tralongo AC, Del Re M, Facchinetti F, Ferrara R, Franchina T, Graziano P, Malapelle U, Menis J, Passaro A, Pilotto S, Ramella S, Rossi G, Trisolini R, Cinquini M, Passiglia F, Novello S
doi: 10.1016/j.lungcan.2024.107990
RECOMMENDED
Lung Cancer
Current diagnostic and therapeutical approaches to bone metastases in patients with non-small cell lung cancer: A cross-sectional study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Avancini A, Giaj-Levra N, Minuti G, Pasqualini G, Colonese F, Federico AD, Fozza A, Montrone M, Olmetto E, Pastorello E, Reale ML, Riva ST, Roca E, Sini C, Viscardi G, Passiglia F, Pilotto S
doi: 10.1016/j.lungcan.2025.108531
RECOMMENDED
Lung Cancer
Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Urtecho SB, Provenzano L, Spagnoletti A, Bottiglieri A, Pircher C, Massa G, Sposetti C, Proto C, Brambilla M, Occhipinti M, Mazzeo L, Beninato T, Leporati R, Giani C, Cavalli C, Serino R, Prina MM, Bassetti A, Nasca V, di Mauro RM, Abate A, Manglaviti S, Dumitrascu AD, Liberti GD, Cassano TS, Ganzinelli M, Wu S, Garassino MC, de Braud FGM, Russo GL, Prelaj A
doi: 10.1016/j.lungcan.2024.108051
Lung Cancer
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial
Lancet Respir Med
Spigel DR, Westeel V, Anderson IC, Greillier L, Guisier F, Bylicki O, Badin FB, Rousseau-Bussac G, Deldycke C, Griesinger F, Bograd A, Zhong W, Le Treut J, Van Hulst S, Gandara DR, Reck M, Hoffknecht P, Gubens MA, Crowley J, von der Leyen H, Woodard GA, Jablons DM, Kratz JR, Mann MJ, AIM-HIGH investigators
doi: 10.1016/S2213-2600(25)00213-9